Literature DB >> 16585167

Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.

Gromoslaw A Smolen1, Beth Muir, Gayatry Mohapatra, Anne Barmettler, Woo J Kim, Miguel N Rivera, Sara M Haserlat, Ross A Okimoto, Eunice Kwak, Sonika Dahiya, Judy E Garber, Daphne W Bell, Dennis C Sgroi, Lynda Chin, Chu-Xia Deng, Daniel A Haber.   

Abstract

In a screen for gene copy number alterations in mouse mammary tumors initiated by loss of the Brca1 and Trp53 genes, we observed that the majority (11 of 15; 73%) had high-level amplification of wild-type Met, encoding a growth factor receptor implicated in tumor progression. Met amplification was localized to unstable double minute chromosomes and was uniquely found in mouse breast tumors driven by loss of Brca1 and Trp53. Whereas analogous MET amplification was not found in human breast cancers, the identification of a dominant somatic genetic lesion in the Brca1/Trp53 mouse model suggests that recurrent secondary hits may also exist in BRCA1-initiated human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585167     DOI: 10.1158/0008-5472.CAN-05-4181

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Met amplification and tumor progression in Cdkn2a-deficient melanocytes.

Authors:  Matthew W Vanbrocklin; James P Robinson; Todd Whitwam; Adam R Guilbeault; Julie Koeman; Pamela J Swiatek; George F Vande Woude; Joseph D Khoury; Sheri L Holmen
Journal:  Pigment Cell Melanoma Res       Date:  2009-04-29       Impact factor: 4.693

2.  Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Authors:  Carrie R Graveel; Jack D DeGroot; Yanli Su; Julie Koeman; Karl Dykema; Samuel Leung; Jacqueline Snider; Sherri R Davies; Pamela J Swiatek; Sandra Cottingham; Mark A Watson; Matthew J Ellis; Robert E Sigler; Kyle A Furge; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-30       Impact factor: 11.205

3.  Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon.

Authors:  Michael Overholtzer; Jianmin Zhang; Gromoslaw A Smolen; Beth Muir; Wenmei Li; Dennis C Sgroi; Chu-Xia Deng; Joan S Brugge; Daniel A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-07       Impact factor: 11.205

4.  Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.

Authors:  Keli Xu; Jerry Usary; Philaretos C Kousis; Aleix Prat; Dong-Yu Wang; Jessica R Adams; Wei Wang; Amanda J Loch; Tao Deng; Wei Zhao; Robert Darrell Cardiff; Keejung Yoon; Nicholas Gaiano; Vicki Ling; Joseph Beyene; Eldad Zacksenhaus; Tom Gridley; Wey L Leong; Cynthia J Guidos; Charles M Perou; Sean E Egan
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

5.  Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.

Authors:  Stefan Heindl; Evelyn Eggenstein; Simone Keller; Julia Kneissl; Gisela Keller; Kathrin Mutze; Sandra Rauser; Georg Gasteiger; Ingo Drexler; Alexander Hapfelmeier; Heinz Höfler; Birgit Luber
Journal:  J Cancer Res Clin Oncol       Date:  2012-05       Impact factor: 4.553

6.  The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma.

Authors:  Daniella Bianchi-Frias; Susana A Hernandez; Roger Coleman; Hong Wu; Peter S Nelson
Journal:  Mol Cancer Res       Date:  2014-10-08       Impact factor: 5.852

7.  Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.

Authors:  Shubing Zhang; Wen-cheng Chung; Lucio Miele; Keli Xu
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

Review 8.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

Review 9.  The Met oncogene and basal-like breast cancer: another culprit to watch out for?

Authors:  Stefania Gastaldi; Paolo M Comoglio; Livio Trusolino
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

10.  Genetic targeting of the kinase activity of the Met receptor in cancer cells.

Authors:  Sabrina Arena; Alberto Pisacane; Massimiliano Mazzone; Paolo Maria Comoglio; Alberto Bardelli
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.